- Home
- LCTX vs PZC Comparison
LCTX vs PZC Comparison
Compare LCTX & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- PZC
- Stock Information
- Founded
- LCTX 1990
- PZC 2002
- Country
- LCTX United States
- PZC United States
- Employees
- LCTX N/A
- PZC N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- PZC Investment Managers
- Sector
- LCTX Health Care
- PZC Finance
- Exchange
- LCTX Nasdaq
- PZC Nasdaq
- Market Cap
- LCTX 107.3M
- PZC N/A
- IPO Year
- LCTX N/A
- PZC N/A
- Fundamental
- Price
- LCTX $1.02
- PZC $6.27
- Analyst Decision
- LCTX Strong Buy
- PZC
- Analyst Count
- LCTX 5
- PZC 0
- Target Price
- LCTX $4.20
- PZC N/A
- AVG Volume (30 Days)
- LCTX 4.6M
- PZC 48.2K
- Earning Date
- LCTX 08-07-2025
- PZC 01-01-0001
- Dividend Yield
- LCTX N/A
- PZC 4.68%
- EPS Growth
- LCTX N/A
- PZC N/A
- EPS
- LCTX N/A
- PZC N/A
- Revenue
- LCTX $9,557,000.00
- PZC N/A
- Revenue This Year
- LCTX N/A
- PZC N/A
- Revenue Next Year
- LCTX $232.66
- PZC N/A
- P/E Ratio
- LCTX N/A
- PZC N/A
- Revenue Growth
- LCTX 19.42
- PZC N/A
- 52 Week Low
- LCTX $0.37
- PZC $6.30
- 52 Week High
- LCTX $1.15
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- LCTX 66.66
- PZC 60.64
- Support Level
- LCTX $0.85
- PZC $6.13
- Resistance Level
- LCTX $1.15
- PZC $6.29
- Average True Range (ATR)
- LCTX 0.12
- PZC 0.04
- MACD
- LCTX -0.00
- PZC 0.02
- Stochastic Oscillator
- LCTX 69.57
- PZC 88.89
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.